Creating a world leader in genetic diagnostics and interpretation for rare diseases and oncology.

Centogene is the global market leader in the testing and interpretation of genetic data for rare diseases and oncology, a market with sustained growth prospects. The company holds the world’s largest portfolio of genetic tests for rare diseases and oncology with activity in more than 120 countries.

Despite significant efforts by national initiatives and pharma companies, there is still a substantial unmet need for diagnosis and treatment of rare diseases. Centogene is uniquely positioned to cost-effectively develop biomarkers and to support global pharma companies in developing new drugs, as well as in screening and monitoring patients.

Careventures invested in Centogene together with other leading healthcare and international biotech investors. The capital injected in the company is contributing to accelerate its growth and expansion plans in the business segments of worldwide genetic testing, pharmaceutical collaborations and big data solutions.